|
Age, y (Mean SD)
|
66.32 ± 9.97
|
68.68 ± 9.63
| |
0.005
|
|
NIHSS score, median (IQR)
|
7(5–11)
|
13(10–16)
| |
<0.001
|
|
D-dimer, median (IQR)
|
1.30(0.80–2.00)
|
2.50(1.60–3.88)
| |
<0.001
|
|
INR, median (IQR)
|
1.34(1.06–1.97)
|
1.37(1.10–1.93)
| |
0.838
|
|
CHA2DS2-VASc, median (IQR)
|
4.00(4–5)
|
4.0(4–5)
| |
0.360
|
|
Infarct volume, ml, median (IQR)
|
51(29–76)
|
81(50–127)
| |
<0.001
|
|
CURB-65 score, median (IQR)
|
2(1–2)
|
2(1–3)
| |
0.005
|
|
Females, n(%)
|
88(47.06)
|
123(53.95)
|
1.32 (0.89–1.94)
|
0.163
|
|
Male, n(%)
|
99(52.94)
|
105(46.05)
|
1.32 (0.89–1.94)
|
0.163
|
|
BMI ≥ 24 kg/m, n(%)
|
55(29.41)
|
68(29.82)
|
1.02(0.67–1.56)
|
0.927
|
|
Hypertension, n(%)
|
120(64.17)
|
145(63.60)
|
0.98(0.65–1.46)
|
0.904
|
|
Current Smoking, n(%)
|
51(27.27)
|
75(32.89)
|
1.31(0.86–2.00)
|
0.215
|
|
Current alcohol drinking,n(%)
|
66(35.29)
|
81(35.53)
|
1.01(0.67–1.51)
|
0.961
|
|
Diabetes, n(%)
|
58(31.01)
|
65(28.51)
|
0.89(0.58–1.35)
|
0.578
|
|
Hyperlipidemia, n(%)
|
121(64.71)
|
157(68.86)
|
1.21(0.80–1.82)
|
0.371
|
|
Family history of stroke, n(%)
|
46(24.60)
|
48(21.05)
|
0.82(0.52–1.30)
|
0.390
|
|
Thrombolytic therapy, n(%)
|
26(13.90)
|
25(10.96)
|
0.76(0.42–1.37)-
|
0.763
|
|
Thrombectomy, n(%)
|
10(5.35)
|
13(5.70)
|
1.07(0.46–2.50)
|
0.875
|
|
Thrombolytic therapy+ Thrombectomy, n(%)
|
4(2.14)
|
4(1.75)
|
0.82(0.20–3.31)
|
0.777
|
|
Medications use
|
|
Antihypertensive, n(%)
|
96(51.34)
|
133(58.33)
|
1.38(0.90–1.96)
|
0.154
|
|
Anticoagulant, n(%)
|
61(32.62)
|
21(9.21)
|
0.21(0.12–0.36)
|
0.000
|
|
Antiplatelets, n(%)
|
54(28.88)
|
55(24.12)
|
0.78(0.51–1.21)
|
0.274
|
|
Lipid-lowering medications, n(%)
|
109(58.29)
|
132(57.89)
|
0.98(0.67–1.46)
|
0.935
|
